136 related articles for article (PubMed ID: 28287008)
41. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
42. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.
Marchetti M
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):469-480. PubMed ID: 28796569
[TBL] [Abstract][Full Text] [Related]
44. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.
Erçalışkan A; Seyhan Erdoğan D; Eşkazan AE
Blood Adv; 2021 Sep; 5(17):3344-3353. PubMed ID: 34477815
[TBL] [Abstract][Full Text] [Related]
45. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
46. Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511.
Yokoo M; Kubota Y; Tabe Y; Kimura S
Biol Pharm Bull; 2015; 38(3):411-6. PubMed ID: 25757922
[TBL] [Abstract][Full Text] [Related]
47. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
Kim K; McMillin GA; Bernard PS; Tantravahi S; Walker BS; Schmidt RL
PLoS One; 2019; 14(12):e0226552. PubMed ID: 31869360
[TBL] [Abstract][Full Text] [Related]
48. How we will treat chronic myeloid leukemia in 2016.
Talati C; Ontiveros EP; Griffiths EA; Wang ES; Wetzler M
Blood Rev; 2015 Mar; 29(2):137-42. PubMed ID: 25555325
[TBL] [Abstract][Full Text] [Related]
49. Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.
Gomez-de-León A; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Arguelles GJ
Expert Rev Hematol; 2017 Sep; 10(9):809-819. PubMed ID: 28742419
[TBL] [Abstract][Full Text] [Related]
50. [Chronic myeloid leukemia – a model disease for targeted therapy].
Richter J; Stenke L
Lakartidningen; 2017 Sep; 114():. PubMed ID: 28949401
[TBL] [Abstract][Full Text] [Related]
51. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
52. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
53. Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
Awidi A; Abbasi S; Alrabi K; Kheirallah KA
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e55-e61. PubMed ID: 28844599
[TBL] [Abstract][Full Text] [Related]
54. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
55. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
[TBL] [Abstract][Full Text] [Related]
56. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era.
Pasquini MC
Hematology; 2012 Apr; 17 Suppl 1():S79-82. PubMed ID: 22507787
[TBL] [Abstract][Full Text] [Related]
57. The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.
Eskazan AE
J Med Econ; 2018 Jul; 21(7):709-711. PubMed ID: 29673265
[No Abstract] [Full Text] [Related]
58. Optimizing the Use of TKIs in the Management of Chronic Myelogenous Leukemia.
Ruiz-Cordell K; Haimowitz S; Gracie-King L; Middleton D
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):442-6. PubMed ID: 27289562
[TBL] [Abstract][Full Text] [Related]
59. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Experts in Chronic Myeloid Leukemia
Blood; 2013 May; 121(22):4439-42. PubMed ID: 23620577
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
Abou Dalle I; Kantarjian H; Burger J; Estrov Z; Ohanian M; Verstovsek S; Ravandi F; Borthakur G; Garcia-Manero G; Jabbour E; Cortes J
Cancer Med; 2019 Nov; 8(15):6559-6565. PubMed ID: 31502383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
